
Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.

GLP-1 Mimetic Benefits Are Broad, New Study Finds, But Risks Can't Be Ignored

Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.

Shagun Bindlish, MD, board member of the American Diabetes Association, details available options for treating venous disease in patients with obesity.

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.

Caissa Troutman, MD, provides an overview of the connection between obesity and hypertension.

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.

President of the Obesity Medicine Association discusses a recent joint statement from the OMA and 4 other organizations calling for inclusion of patients with obesity in drug research.

The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.

Angela Fitch, MD, discusses the importance of clinician education in addressing obesity with patients.

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

"Twincretin" tirzepatide-treated participants in SURMOUNT-5 lost a mean 50 lbs vs an average loss of 33 lbs for those treated with semaglutide.

In a study of adults enrolled in a telehealth weight management program, 45% decreased their alcohol use after taking antiobesity medication.

The proposal would expand antiobesity drug access for more than 7 million people with Medicare and Medicaid coverage.

The investigational weight loss drug showed substantial weight loss among people with obesity or overweight with or without T2D without plateaus.

Your daily dose of the clinical news you may have missed.

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.